Terapi Bisfosfonat untuk Pasien Osteoporosis Pasca-Menopause

Penulis

  • Noviana Joenputri Departemen Ilmu Penyakit Dalam, Rumah Sakit Umum Daerah Wangaya, Denpasar, Bali, Indonesia

DOI:

https://doi.org/10.55175/cdk.v47i8.578

Kata Kunci:

Bisfosfonat, osteoporosis, pasca-menopause, pengobatan

Abstrak

Osteoporosis lebih sering terjadi pada wanita pasca-menopause karena perubahan hormon yang menyebabkan ketidakseimbangan antara resorpsi dan pembentukan tulang. Osteoporosis dapat menyebabkan patah tulang yang akan berdampak pada peningkatan morbiditas dan mortalitas. Terapi saat ini bertujuan untuk mencegah patah tulang serta menjaga dan meningkatkan densitas mineral tulang. Bisfosfonat merupakan obat yang paling sering digunakan untuk terapi osteoporosis pasca-menopause. The US Food and Drug Administration (FDA) telah menyetujui 4 agen bisfosfonat, yaitu alendronat, risedronat, ibandronat, dan asam zoledronat. Bisfosfonat memiliki beberapa efek samping yang perlu diperhatikan akibat penggunaan jangka panjang. Kepatuhan pengobatan osteoporosis memiliki hubungan kuat dengan risiko patah tulang.

Osteoporosis is more common in post-menopausal women, as hormonal changes cause an imbalance between bone resorption and formation. Osteoporosis can cause fractures that will contribute to morbidity and mortality. Current therapies aim to prevent fractures, maintain and increase bone mineral density. Biphosphonates are the most widely used drugs for postmenopausal osteoporosis treatment. The US Food and Drug Administration (FDA) has approved 4 biphosphonate agents: alendronate, risedronate, ibandronate, and zoledronic acid. Biphosphonates have several side effects that need to be considered due to long-term use. Compliance and adherence in the treatment of osteoporosis has a strong relationship to risk of fractures

Unduhan

Data unduhan belum tersedia.

Referensi

National Osteoporosis Foundation. America’s bone health: The state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation; 2002.

United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: The 2017 revision [Internet]. 2017 [cited 2020 Apr 18]. Available from: https://population.un.org/wpp/Graphs/DemographicProfiles/

Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137-41.

The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:25–54.

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation. Osteoporos Int. 2014;25(10):2359-81.

Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. Endocrine Practice. 2016;22(s4):1-42.

Azagra R, Roca G, Encabo G, Aguye A, Zwart M, Guell S, et al. FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort. BMC Musculoskelet Disord. 2012;13:204. https://doi.org/10.1186/1471-2474-13-204

American Association of Clinical Endocrinologist. Postmenopausal osteoporosis guidelines. Endocr Pract. 2010;16(Suppl 3).

Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 Suppl):14-21.

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabolism. 2019;104(5):1595-622.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorders (CKD-MBD). Kidney Int Suppl. 2009; 76(suppl 113):1-130.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.

Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82

Black DM, Schwartz AV, Ensrud KE, et al, for the FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). A randomized trial. JAMA. 2006;296:2927-38.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA. 1999; 282:1344-52.

Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-9.

Sörensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstorm D, et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone. 2003;32:120-6.

Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, et al. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013;93(2):137–46.

Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkerstad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in post-menopausal osteoporosis. J Bone Miner Res. 2004;19:1241-9.

Lee YH, Song GG. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trial. Korean J Intern Med. 2011;26:340-7.

Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration Study. Arthritis Rheum. 2006;54:1838-46.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JY, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22.

Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, et al. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).Osteoporos Int. 2017; 28(1): 389–98.

Räkel A, Boucher A, Ste-Marie LG. Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging. 2011;6:89-99.

Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811-8.

Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453-60.

Imaz I, Zegarra O, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic reviewand meta-analysis. Osteoporos Int. 2010;21:1943–51.

Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254-62.

Modi A, Siris ES, Tang J, Sen S. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Curr Med Res Opin. 2015; 31:757-65.

Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16–35.

Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002–2012. Bone. 2013;57(2):423-8.

Kennel KA, Drake MT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632-8 .

Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74:641-8

Diterbitkan

2020-10-01

Cara Mengutip

Joenputri , N. (2020). Terapi Bisfosfonat untuk Pasien Osteoporosis Pasca-Menopause. Cermin Dunia Kedokteran, 47(8), 592–596. https://doi.org/10.55175/cdk.v47i8.578

Terbitan

Bagian

Articles